Hernández Madrid Antonio, Potpara Tatjana S, Dagres Nikolaos, Chen Jian, Larsen Torben B, Estner Heidi, Todd Derick, Bongiorni Maria G, Sciaraffia Elena, Proclemer Alessandro, Cheggour Saida, Amara Walid, Blomstrom-Lundqvist Carina
Cardiology Department, Ramón y Cajal Hospital, Alcala University, Ctra.Colmenar Viejo, km 9,100, Madrid 28034, Spain
School of Medicine, University of Belgrade, Belgrade, Serbia Cardiology Clinic, Clinical Center of Serbia, Serbia.
Europace. 2016 Mar;18(3):463-7. doi: 10.1093/europace/euv448. Epub 2016 Feb 21.
The purpose of this patient survey was to analyse the knowledge about blood thinning medications relative to gender, age, education, and region of residence in patients with atrial fibrillation (AF). A total of 1147 patients with AF [mean age 66 ± 13 years, 529 (45%) women] from eight European countries responded to this survey. Most patients understood that the indication for anticoagulation therapy was to 'thin the blood', but 8.1% responded that the purpose of the medication was to treat the arrhythmia. Patients with college or university grades reported less frequent deviations from their target INR range compared with those without schooling (2.8% vs. 5.1%, P < 0.05). The awareness of anticoagulation-related risk of bleedings was lowest in patients without schooling (38.5%) and highest in those with college and university education (57.0%), P < 0.05. The same pattern was also observed regarding patient's awareness of non-vitamin K antagonist oral anticoagulants (NOACs): 56.5% of the patients with university education and only 20.5% of those without schooling (P < 0.05) knew about NOACs, indicating that information about new anticoagulation therapies remains well below the target. Bleeding events were statistically less frequent in patients on NOACs compared with vitamin K antagonists. The education level and patients' knowledge have a direct influence on the global management of the anticoagulation.
这项患者调查的目的是分析心房颤动(AF)患者在血液稀释药物方面与性别、年龄、教育程度和居住地区相关的知识。来自八个欧洲国家的总共1147名AF患者[平均年龄66±13岁,529名(45%)女性]对该调查做出了回应。大多数患者理解抗凝治疗的指征是“稀释血液”,但8.1%的患者回答药物的目的是治疗心律失常。与未受过教育的患者相比,具有大专或大学学历的患者报告的国际标准化比值(INR)偏离目标范围的频率较低(2.8%对5.1%,P<0.05)。未受过教育的患者对抗凝相关出血风险的知晓率最低(38.5%),而具有大专和大学学历的患者知晓率最高(57.0%),P<0.05。在患者对非维生素K拮抗剂口服抗凝药(NOACs)的知晓方面也观察到了相同的模式:56.5%受过大学教育的患者和只有20.5%未受过教育的患者(P<0.05)了解NOACs,这表明关于新型抗凝治疗的信息仍远低于目标水平。与维生素K拮抗剂相比,服用NOACs的患者出血事件在统计学上较少。教育水平和患者知识对抗凝的整体管理有直接影响。